Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics. His stories explore how tech is changing the practice of health care and the business and policy challenges to realizing tech’s promise. He’s also the co-author of the free, twice weekly STAT Health Tech newsletter. You can reach Mario on Signal at mariojoze.13.

Cognito Therapeutics on Thursday said it has raised $105 million as it awaits clinical trial results it hopes will catapult its Alzheimer’s treatment device to Food and Drug Administration clearance.

The Series C round was led by Morningside Ventures, IAG Capital Partners, and Starbloom Capital, with participation from new investors New Vintage, Apollo Health Ventures, and Benvolio Group. The company has raised $233 million to date.

Founded nearly a decade ago, Cognito is developing Spectris, a sensory stimulus device that looks a bit like a pair of sunglasses connected to over-ear headphones. Based on research from the Massachusetts Institute of Technology, the device beams patients with gamma frequency light and sound for an hour a day. The stimulus is meant to restore brain activity disrupted by neurodegenerative conditions.

STAT+ Exclusive Story

STAT+



This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Individual plans

Group plans

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe